La obesidad abdominal es esencial para el riesgo de tromboembolismo venoso en el síndrome metabólico: el estudio de tromso / Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the thrombus study

ANTECEDENTES: el síndrome metabólico es un conjunto de factoresde riesgo cardiovascular, como la obesidad abdominal, hipertensión, dislipidemia y resistenciaa la insulina, asociado con un mayor riesgo de enfermedades cardiovasculares y mortalidad porcualquier causa. OBJETIVOS: el propósito del estudio fue evaluar el impacto del síndrome metabólico y sus componentes individuales, sobre el riesgo de tromboembolismo venoso (TEV) en un estudio poblacional prospectivo. MÉTODOS: Los componentes individuales del síndrome metabólico se registraron en 6170 sujetos de 25 a84 años en el Estudio de Tromsø en 1994-1995, y por primera vez los eventos de TEV se registraron hasta el 1 de septiembre de 2007...

Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study.

SUMMARY BACKGROUND: The metabolic syndrome is a cluster of cardiovascular risk factors, including abdominal obesity, hypertension, dyslipidemia and insulin resistance, associated with increased risk of cardiovascular diseases and all cause mortality. OBJECTIVES: The purpose of the study was to assess the impact of the metabolic syndrome, and its individual components, on the risk of venous thromboembolism (VTE) in a prospective population-based study. METHODS: Individual components of the metabolic syndrome were registered in 6170 subjects aged 25-84 years in the Tromsø Study in 1994-1995, and first ever VTE events were registered until 1 September 2007. RESULTS: The metabolic syndrome was present in 21.9% (1350 subjects) of the population. There were 194 validated first VTE events (2.92 per 1000 person-years) during a mean of 10.8 years of follow-up. Presence of metabolic syndrome was associated with increased risk of VTE (HR, 1.65; 95% CI, 1.22-2.23) in age- and gender-adjusted analysis. The risk of VTE increased with the number of components in the metabolic syndrome (P < 0.001). Abdominal obesity was the only component significantly associated with VTE in multivariable analysis including age, gender, and the individual components of the syndrome (HR, 2.03; 95% CI, 1.49-2.75). When abdominal obesity was omitted as a diagnostic criterion, none of the other components, alone or in cluster, was associated with increased risk of VTE. CONCLUSIONS: Our study provides evidence for the metabolic syndrome as a risk factor for TE. Abdominal obesity appeared to be the pivotal risk factor among the individual components of the syndrome.